Share on StockTwits

Opexa Therapeutics (NASDAQ:OPXA) issued its quarterly earnings data on Thursday. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.02, StockRatingsNetwork reports.

On a related note, analysts at Aegis initiated coverage on shares of Opexa Therapeutics in a research note on Friday, May 30th. They set a “buy” rating and a $4.00 price target on the stock.

Opexa Therapeutics (NASDAQ:OPXA) traded up 1.32% on Thursday, hitting $1.53. The stock had a trading volume of 84,104 shares. Opexa Therapeutics has a 52 week low of $1.26 and a 52 week high of $2.56. The stock’s 50-day moving average is $1.57 and its 200-day moving average is $1.65. The company’s market cap is $42.3 million.

Opexa Therapeutics, Inc (NASDAQ:OPXA) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.